Literature DB >> 20139279

Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity.

John Sidney1, Amiyah Steen, Carrie Moore, Sandy Ngo, Jolan Chung, Bjoern Peters, Alessandro Sette.   

Abstract

Compared with DR and DQ, knowledge of the binding repertoires and specificities of HLA-DP alleles is somewhat limited. However, a growing body of literature has indicated the importance of DP-restricted responses in the context of cancer, allergy, and infectious disease. In the current study, we developed high-throughput binding assays for the five most common HLA-DPB1 alleles in the general worldwide population. Using these assays on a comprehensive panel of single-substitution analogs and large peptide libraries, we derived novel detailed binding motifs for DPB1*0101 and DPB1*0501. We also derived more detailed quantitative motifs for DPB1*0201, DPB1*0401, and DPB1*0402, which were previously characterized on the basis of sets of eluted ligands and/or limited sets of substituted peptides. Unexpectedly, all five DP molecules, originally selected only on the basis of their frequency in human populations, were found to share largely overlapping peptide motifs. Testing panels of known DP epitopes and a panel of peptides spanning a set of Phleum pratense Ags revealed that these molecules also share largely overlapping peptide-binding repertoires. This demonstrates that a previously hypothesized DP supertype extends far beyond what was originally envisioned and includes at least three additional very common DP specificities. Taken together, these DP supertype molecules are found in >90% of the human population. Thus, these findings have important implications for epitope-identification studies and monitoring of human class II-restricted immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139279      PMCID: PMC2935290          DOI: 10.4049/jimmunol.0903655

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  86 in total

1.  Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs.

Authors:  Gema Díaz; Benito Cañas; Jesús Vazquez; César Nombela; Javier Arroyo
Journal:  Immunogenetics       Date:  2004-11-24       Impact factor: 2.846

2.  On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs.

Authors:  D O'Sullivan; T Arrhenius; J Sidney; M F Del Guercio; M Albertson; M Wall; C Oseroff; S Southwood; S M Colón; F C Gaeta
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

3.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

4.  A biological role for the major histocompatibility antigens.

Authors:  P C Doherty; R M Zinkernagel
Journal:  Lancet       Date:  1975-06-28       Impact factor: 79.321

5.  Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype.

Authors:  D Ou; L A Mitchell; D Décarie; A J Tingle; G T Nepom
Journal:  Hum Immunol       Date:  1998-03       Impact factor: 2.850

6.  Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein.

Authors:  C Yun; S Senju; H Fujita; Y Tsuji; A Irie; S Matsushita; Y Nishimura
Journal:  Tissue Antigens       Date:  1999-08

7.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  HLA class I supertypes: a revised and updated classification.

Authors:  John Sidney; Bjoern Peters; Nicole Frahm; Christian Brander; Alessandro Sette
Journal:  BMC Immunol       Date:  2008-01-22       Impact factor: 3.615

9.  SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens.

Authors:  Vandana Gupta; Tani M Tabiin; Kai Sun; Ananth Chandrasekaran; Azlinda Anwar; Kun Yang; Priya Chikhlikar; Jerome Salmon; Vladimir Brusic; Ernesto T A Marques; Srinivasan N Kellathur; Thomas J August
Journal:  Virology       Date:  2006-01-04       Impact factor: 3.616

10.  Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.

Authors:  K W Wucherpfennig; A Sette; S Southwood; C Oseroff; M Matsui; J L Strominger; D A Hafler
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  58 in total

1.  Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign.

Authors:  Massimo Andreatta; Morten Nielsen
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

2.  HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

Authors:  Marcel van Lith; Rosanna M McEwen-Smith; Adam M Benham
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

3.  Selected human leukocyte antigen class II polymorphisms and risk of adult glioma.

Authors:  Bryan A Bassig; Peter D Inskip; Laurie Burdette; William R Shapiro; Robert G Selker; Howard A Fine; Jay S Loeffler; Peter M Black; Robert Dubrow; Alina V Brenner
Journal:  J Neuroimmunol       Date:  2010-12-30       Impact factor: 3.478

4.  Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C.

Authors:  Cibele M Gaido; Shane Stone; Abha Chopra; Wayne R Thomas; Peter N Le Souëf; Belinda J Hales
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

6.  Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery.

Authors:  Jonathan R Honegger; Dana Tedesco; Jennifer A Kohout; Mona R Prasad; Aryn A Price; Tera Lindquist; Samantha Ohmer; Melissa Moore-Clingenpeel; Arash Grakoui; Christopher M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 7.  The identification of potentially pathogenic and therapeutic epitopes from common human allergens.

Authors:  Véronique Schulten; Carla Oseroff; Rafeul Alam; David Broide; Pandurangan Vijayanand; Bjoern Peters; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2012-11-15       Impact factor: 6.347

8.  Peptide binding predictions for HLA DR, DP and DQ molecules.

Authors:  Peng Wang; John Sidney; Yohan Kim; Alessandro Sette; Ole Lund; Morten Nielsen; Bjoern Peters
Journal:  BMC Bioinformatics       Date:  2010-11-22       Impact factor: 3.169

9.  MultiRTA: a simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes.

Authors:  Andrew J Bordner; Hans D Mittelmann
Journal:  BMC Bioinformatics       Date:  2010-09-24       Impact factor: 3.169

10.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.